About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 580135, 8 pages
http://dx.doi.org/10.1155/2013/580135
Research Article

TNFα Mediated IL-6 Secretion Is Regulated by JAK/STAT Pathway but Not by MEK Phosphorylation and AKT Phosphorylation in U266 Multiple Myeloma Cells

1Cancer Research Institute, College of Medicine, Seoul National University, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
2Clinical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
3Hematology and Medical Oncology, Dongguk University Ilsan Hospital, 27 Dongguk-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-773, Republic of Korea
4Department of Laboratory Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea
5Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, Seoul 110-799, Republic of Korea

Received 7 June 2013; Revised 15 August 2013; Accepted 16 August 2013

Academic Editor: Susanne Saussele

Copyright © 2013 Chansu Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Hideshima and K. C. Anderson, “Molecular mechanisms of novel therapeutic approaches for multiple myeloma,” Nature Reviews Cancer, vol. 2, no. 12, pp. 927–937, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Singhal and J. Mehta, “Novel therapies in multiple myeloma,” International Journal of Hematology, vol. 77, no. 3, pp. 226–231, 2003. View at Scopus
  3. T. Hideshima, D. Chauhan, K. Podar, R. L. Schlossman, P. Richardson, and K. C. Anderson, “Novel therapies targeting the myeloma cell and its bone marrow microenvironment,” Seminars in Oncology, vol. 28, no. 6, pp. 607–612, 2001. View at Scopus
  4. M. B. Meads, L. A. Hazlehurst, and W. S. Dalton, “The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance,” Clinical Cancer Research, vol. 14, no. 9, pp. 2519–2526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Nefedova, T. H. Landowski, and W. S. Dalton, “Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms,” Leukemia, vol. 17, no. 6, pp. 1175–1182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Podar, P. G. Richardson, T. Hideshima, D. Chauhan, and K. C. Anderson, “The malignant clone and the bone-marrow environment,” Best Practice and Research in Clinical Haematology, vol. 20, no. 4, pp. 597–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. S. Mitsiades, D. W. McMillin, S. Klippel et al., “The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies,” Hematology/Oncology Clinics of North America, vol. 21, no. 6, pp. 1007–1034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Alexandrakis, F. H. Passam, A. Sfiridaki, E. Kandidaki, P. Roussou, and D. S. Kyriakou, “Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity,” The American Journal of Hematology, vol. 72, no. 4, pp. 229–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Cao, T. Luetkens, S. Kobold et al., “The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients,” Experimental Hematology, vol. 38, no. 10, pp. 860–867, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Aggarwal, I. M. Ghobrial, and G. D. Roodman, “Chemokines in multiple myeloma,” Experimental Hematology, vol. 34, no. 10, pp. 1289–1295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Coe, R. Irwin, D. Lippner, and L. R. McCabe, “The bone marrow microenvironment contributes to type I diabetes induced osteoblast death,” Journal of Cellular Physiology, vol. 226, no. 2, pp. 477–483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Lu, G. R. Beck Jr., L. C. Gilbert et al., “Identification of the homeobox protein Prx1 (MHox, Prrx-1) as a regulator of osterix expression and mediator of tumor necrosis factor α action in osteoblast differentiation,” Journal of Bone and Mineral Research, vol. 26, no. 1, pp. 209–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Bommert, R. C. Bargou, and T. Stühmer, “Signalling and survival pathways in multiple myeloma,” European Journal of Cancer, vol. 42, no. 11, pp. 1574–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Kawano, H. Ishikawa, N. Tsuyama et al., “Growth mechanism of human myeloma cells by interleukin-6,” International Journal of Hematology, vol. 76, supplement 1, pp. 329–333, 2002. View at Scopus
  15. R. D. Devlin, S. V. Reddy, R. Savino, G. Ciliberto, and G. D. Roodman, “IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures,” Journal of Bone and Mineral Research, vol. 13, no. 3, pp. 393–399, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Baud and M. Karin, “Is NF-κB a good target for cancer therapy? Hopes and pitfalls,” Nature Reviews Drug Discovery, vol. 8, no. 1, pp. 33–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Zdzisińska, A. Bojarska-Junak, A. Dmoszyńska, and M. Kandefer-Szerszeń, “Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells,” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 3, pp. 207–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Wajant, K. Pfizenmaier, and P. Scheurich, “Tumor necrosis factor signaling,” Cell Death and Differentiation, vol. 10, no. 1, pp. 45–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Chen and D. V. Goeddel, “TNF-R1 signaling: a beautiful pathway,” Science, vol. 296, no. 5573, pp. 1634–1635, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Thompson, T. E. Witzig, S. Kumar et al., “Plasma levels of tumour necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma,” The British Journal of Haematology, vol. 123, no. 2, pp. 305–308, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. H. I. A. Sati, M. Greaves, J. F. Apperley, R. G. G. Russell, and P. I. Croucher, “Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma,” The British Journal of Haematology, vol. 104, no. 2, pp. 350–357, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Lichtenstein, J. Berenson, D. Norman, M. P. Chang, and A. Carlile, “Production of cytokines by bone marrow cells obtained from patients with multiple myeloma,” Blood, vol. 74, no. 4, pp. 1266–1273, 1989. View at Scopus
  24. S. Markovina, N. S. Callander, S. L. O'Connor et al., “Bortezomib-resistant nuclear factor-κB activity in multiple myeloma cells,” Molecular Cancer Research, vol. 6, no. 8, pp. 1356–1364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Chauhan, H. Uchiyama, Y. Akbarali et al., “Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB,” Blood, vol. 87, no. 3, pp. 1104–1112, 1996. View at Scopus
  26. T. Sanda, S. Iida, H. Ogura et al., “Growth inhibition of multiple myeloma cells by a novel IκB kinase inhibitor,” Clinical Cancer Research, vol. 11, no. 5, pp. 1974–1982, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Dai, X. Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant, “Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells,” Blood, vol. 103, no. 7, pp. 2761–2770, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Hideshima, P. Neri, P. Tassone et al., “MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo,” Clinical Cancer Research, vol. 12, no. 19, pp. 5887–5894, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. K. H. Ha, M. S. Byun, J. Choi, J. Jeong, K. J. Lee, and D. M. Jue, “N-tosyl-L-phenylalanine chloromethyl ketone inhibits NF-κB activation by blocking specific cysteine residues of IκB kinase β and p65/RelA,” Biochemistry, vol. 48, no. 30, pp. 7271–7278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Wang, J. L. Abbruzzese, D. B. Evans, and P. J. Chiao, “Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA,” Oncogene, vol. 18, no. 32, pp. 4554–4563, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. O. W. Rokhlin, N. V. Guseva, A. F. Taghiyev, R. A. Glover, and M. B. Cohen, “Multiple effects of N-α-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines,” Cancer Biology and Therapy, vol. 3, no. 8, pp. 761–768, 2004. View at Scopus